Published in Gastroenterology on March 09, 2009
Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 3.05
Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology (2009) 2.22
Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol (2013) 2.16
Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog (2013) 1.54
Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc Natl Acad Sci U S A (2010) 1.49
Defining the Roles of IFN-γ and IL-17A in Inflammation and Protection against Helicobacter pylori Infection. PLoS One (2015) 1.43
The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol (2010) 1.17
Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol (2011) 1.14
The immunomodulatory properties of Helicobacter pylori confer protection against allergic and chronic inflammatory disorders. Front Cell Infect Microbiol (2012) 1.13
Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS One (2010) 1.13
Th17 cytokines and vaccine-induced immunity. Semin Immunopathol (2010) 1.07
Regulation of gastric B cell recruitment is dependent on IL-17 receptor A signaling in a model of chronic bacterial infection. J Immunol (2009) 1.04
Downregulated Th17 responses are associated with reduced gastritis in Helicobacter pylori-infected children. Mucosal Immunol (2013) 1.03
Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infect Immun (2010) 1.00
Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide. Trends Immunol (2010) 0.97
Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase. Infect Immun (2010) 0.97
Th17 cell based vaccines in mucosal immunity. Curr Opin Immunol (2013) 0.95
TLR2 mediates Helicobacter pylori-induced tolerogenic immune response in mice. PLoS One (2013) 0.93
Vaccine-induced immunity against Helicobacter pylori in the absence of IL-17A. Helicobacter (2011) 0.92
Diversity of IL-17-producing T lymphocytes. Cell Mol Life Sci (2012) 0.91
Immune responses to Helicobacter pylori infection. World J Gastroenterol (2014) 0.90
Effects of myeloid differentiation primary response gene 88 (MyD88) activation on Helicobacter infection in vivo and induction of a Th17 response. Helicobacter (2011) 0.90
H. pylori vaccines: why we still don't have any. Hum Vaccin (2011) 0.90
Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol (2014) 0.90
Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain. Appl Environ Microbiol (2011) 0.88
Inflammation, immunity, and vaccines for Helicobacter pylori infection. Helicobacter (2012) 0.87
The role of Th cell subsets in the control of Helicobacter infections and in T cell-driven gastric immunopathology. Front Immunol (2012) 0.86
Immune evasion strategies used by Helicobacter pylori. World J Gastroenterol (2014) 0.85
Helicobacter felis--associated gastric disease in microbiota-restricted mice. J Histochem Cytochem (2011) 0.85
IRAK-M expression limits dendritic cell activation and proinflammatory cytokine production in response to Helicobacter pylori. PLoS One (2013) 0.84
Th1-mediated immunity against Helicobacter pylori can compensate for lack of Th17 cells and can protect mice in the absence of immunization. PLoS One (2013) 0.84
Impaired dendritic cell maturation and IL-10 production following H. pylori stimulation in gastric cancer patients. Appl Microbiol Biotechnol (2012) 0.84
Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity. PLoS One (2013) 0.84
Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions. World J Gastroenterol (2015) 0.83
Role of Inflammatory Monocytes in Vaccine-Induced Reduction of Helicobacter felis Infection. Infect Immun (2015) 0.82
Protease-activated receptor 1 suppresses Helicobacter pylori gastritis via the inhibition of macrophage cytokine secretion and interferon regulatory factor 5. Mucosal Immunol (2014) 0.82
Th1 and Th17 responses to Helicobacter pylori in Bangladeshi infants, children and adults. PLoS One (2014) 0.82
Activation of type I IFN signaling by NOD1 mediates mucosal host defense against Helicobacter pylori infection. Gut Microbes (2011) 0.81
NOD1-Mediated Mucosal Host Defense against Helicobacter pylori. Int J Inflam (2010) 0.81
Role of childhood infection in the sequelae of H. pylori disease. Gut Microbes (2013) 0.80
Vaccinating against Helicobacter pylori in the developing world. Gut Microbes (2013) 0.80
The interleukin-17 receptor B subunit is essential for the Th2 response to Helicobacter pylori, but not for control of bacterial burden. PLoS One (2013) 0.79
Helicobacter pylori vaccination: is there a path to protection? World J Gastroenterol (2014) 0.78
Polarizing the T helper 17 response in Citrobacter rodentium infection via expression of resistin-like molecule α. Gut Microbes (2014) 0.77
Cytokines, cytokine gene polymorphisms and Helicobacter pylori infection: friend or foe? World J Gastroenterol (2014) 0.77
The Immunomodulator VacA Promotes Immune Tolerance and Persistent Helicobacter pylori Infection through Its Activities on T-Cells and Antigen-Presenting Cells. Toxins (Basel) (2016) 0.76
IL-22-induced antimicrobial peptides are key determinants of mucosal vaccine-induced protection against H. pylori in mice. Mucosal Immunol (2016) 0.76
Recombinant Bacillus subtilis Spores Elicit Th1/Th17-Polarized Immune Response in a Murine Model of Helicobacter pylori Vaccination. Mol Biotechnol (2015) 0.75
Induction of mucosal immune responses against Helicobacter pylori infection after sublingual and intragastric route of immunization. Immunology (2016) 0.75
Mechanisms of Cholera Toxin in the Modulation of TH17 Responses. Crit Rev Immunol (2015) 0.75
Leptin, CD4(+) T(reg) and the prospects for vaccination against H. pylori infection. Front Immunol (2012) 0.75
Helicobacter pylori infection. N Engl J Med (2002) 14.81
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology (2003) 3.43
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol (2013) 2.05
The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. J Exp Med (2007) 1.81
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology (2005) 1.71
Influence of Helicobacter pylori infection during atherogenesis in vivo in mice. Circ Res (2002) 1.71
Analysis of the accuracy and robustness of the leap motion controller. Sensors (Basel) (2013) 1.57
Ascites and highly elevated CA-125 levels in a case of peritoneal tuberculosis. Scand J Infect Dis (2006) 1.52
PAR2 promotes vaccine-induced protection against Helicobacter infection in mice. Gastroenterology (2011) 1.52
Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis (2005) 1.45
Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): is it a matter of days? Acta Oncol (2006) 1.43
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.41
European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis (2008) 1.34
Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol (2009) 1.25
Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis (2010) 1.21
Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis (2012) 1.21
Inflammatory gene profiles in gastric mucosa during Helicobacter pylori infection in humans. J Immunol (2004) 1.17
Serrated polyps of the colorectum: is sessile serrated adenoma distinguishable from hyperplastic polyp in a daily practice? Virchows Arch (2007) 1.15
Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics (2002) 1.13
Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps. Histopathology (2009) 1.11
Primary clear cell sarcoma of the ileum: an uncommon and misleading site. Virchows Arch (2005) 1.10
Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol Rep (2007) 1.09
Prospective comparison of MR enteroclysis with multidetector spiral-CT enteroclysis: interobserver agreement and sensitivity by means of "sign-by-sign" correlation. Eur Radiol (2002) 1.07
Metastatic tumors to the colon and rectum: a multi-institutional study. Arch Pathol Lab Med (2012) 1.02
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis (2011) 1.01
Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol (2008) 1.01
Novel markers of the human follicle-associated epithelium identified by genomic profiling and microdissection. Gastroenterology (2005) 1.00
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol (2005) 0.99
Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer. Surgery (2002) 0.98
When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. J Crohns Colitis (2013) 0.96
Advances in vaccination against Helicobacter pylori. Expert Rev Gastroenterol Hepatol (2010) 0.95
Transepithelial transport of HIV-1 by M cells is receptor-mediated. Proc Natl Acad Sci U S A (2002) 0.94
Solitary choriocarcinoma in the lung. J Thorac Oncol (2010) 0.93
Extraintestinal manifestations of Crohn's disease. Digestion (2008) 0.93
Potentiation of polarized intestinal Caco-2 cell responsiveness to probiotics complexed with secretory IgA. J Biol Chem (2010) 0.93
Upper gastrointestinal Crohn's disease. Digestion (2008) 0.93
The role of secretory immunoglobulin A in the natural sensing of commensal bacteria by mouse Peyer's patch dendritic cells. J Biol Chem (2012) 0.92
Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum Gene Ther (2014) 0.91
Defining new criteria for selection of cell-based intestinal models using publicly available databases. BMC Genomics (2012) 0.91
Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology (2007) 0.90
Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine (2002) 0.90
Time-resolved quantitative proteome analysis of in vivo intestinal development. Mol Cell Proteomics (2010) 0.90
Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother (2006) 0.89
Toll-interacting protein modulates colitis susceptibility in mice. Inflamm Bowel Dis (2014) 0.89
Fibrostenotic Crohn's disease. Digestion (2008) 0.88
Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis. World J Gastroenterol (2011) 0.88
Expression of Helicobacter pylori virulence factors and associated expression profiles of inflammatory genes in the human gastric mucosa. Infect Immun (2007) 0.88
Human achaete-scute homologue (hASH1) mRNA level as a diagnostic marker to distinguish esthesioneuroblastoma from poorly differentiated tumors arising in the sinonasal tract. Am J Clin Pathol (2004) 0.87
Inflammation, immunity and vaccines for Helicobacter pylori. Helicobacter (2004) 0.87
Pregnancy and breastfeeding in patients with Crohn's disease. Digestion (2008) 0.85
The role of interval nodes in sentinel lymph node mapping and dissection for melanoma patients. J Nucl Med (2007) 0.85
Primary appendiceal melanoma: fiction or reality? Hum Pathol (2004) 0.85
Obstructive fibrostenotic Crohn's disease. Digestion (2005) 0.85
Extraintestinal manifestations of Crohn's disease. Digestion (2005) 0.85
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis (2015) 0.84
Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients. Scand J Gastroenterol (2014) 0.84
Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother (2007) 0.83
Influence of gut microbiota on mouse B2 B cell ontogeny and function. Mol Immunol (2011) 0.83
Passive immunity in Helicobacter-challenged neonatal mice conferred by immunized dams lasts until weaning. Infect Immun (2003) 0.83
Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis (2009) 0.82
Immunology of Helicobacter pylori infection. Digestion (2006) 0.82
Evaluating appropriateness of treatment for Crohn's disease: feasibility of an explicit approach. Digestion (2007) 0.82
Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study. Inflamm Bowel Dis (2015) 0.81
Characteristics of non-responders to self-reported questionnaires in a large inflammatory bowel disease cohort study. Scand J Gastroenterol (2015) 0.81
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis (2010) 0.81
Treatment of gastroduodenal Crohn's disease. Digestion (2005) 0.81
Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer. Cancer Immun (2008) 0.81
The European Panel on the Appropriateness of Crohn's Disease Therapy. Digestion (2005) 0.81
Rapid transgene expression in multiple precursor cell types of adult rat subventricular zone mediated by adeno-associated type 1 vectors. Hum Gene Ther (2012) 0.81
The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy. Inflamm Bowel Dis (2013) 0.81
Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel - EPACT II. J Crohns Colitis (2009) 0.81
Treatment of postoperative Crohn's disease. Digestion (2005) 0.80
The volatile anesthetic sevoflurane inhibits activation of neutrophil granulocytes during simulated extracorporeal circulation. Int Immunopharmacol (2012) 0.80
Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population-based study in Switzerland. Digestion (2004) 0.80
Human papilloma virus type and recurrence rate after surgical clearance of anal condylomata acuminata. Sex Transm Dis (2009) 0.80
Malakoplakia and colonic adenoma: a rare association. Ann Diagn Pathol (2004) 0.80
Role of secretory IgA in the mucosal sensing of commensal bacteria. Gut Microbes (2014) 0.80
Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome. Eur J Gastroenterol Hepatol (2005) 0.80
Preoperative hyper-fractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC) immediately followed by surgery. A prospective phase II trial. Radiother Oncol (2006) 0.80
An adeno-associated virus-based intracellular sensor of pathological nuclear factor-κB activation for disease-inducible gene transfer. PLoS One (2013) 0.79
Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland): A population-based cohort study. J Crohns Colitis (2007) 0.79
Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease. Digestion (2013) 0.79
Perceived behavioral changes in early multiple sclerosis. Behav Neurol (2007) 0.79
Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. Eur J Gastroenterol Hepatol (2010) 0.79
Drug safety in Crohn's disease therapy. Digestion (2008) 0.79
Inflammation, immunity, vaccines for Helicobacter infection. Helicobacter (2006) 0.79